The landmark approval of sipuleucel-T in 2010 substantiated the viability of prostate cancer immunotherapy, providing level I evidence of a survival benefit in metastatic CRPC despite minimal changes in conventional endpoints such as PSA or imaging responses [65]. Here, KLK3 is linked to Familial prostate cancer.